US Health Secretary Clarifies Non-Involvement in FDA Drug Rejection

Health Secretary Robert F. Kennedy Jr. stated during a Senate hearing that he was not involved in the FDA's decision to reject Replimune's cancer drug, RP1. The FDA reportedly declined approval due to the drug's reliance on a single-arm study, requesting data from a more controlled trial. This regulatory action by the FDA has implications for clinical guidance and patient access to new treatments.